Device Trial Radar · NCT07897760
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
Last checked: Nov 21, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Otto Bock Healthcare Products GmbHNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Ottobock SE & Co. KGaA; Exoneural Network AB; CW-Research & Management GmbH; Otto Bock HealthCare LP
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical research study is investigating whether the EXOPULSE Suit, a wearable device that delivers electrical stimulation, can help improve movement difficulties caused by spasticity in adults with multiple sclerosis (MS). The main goal of the study is to evaluate the effect of the EXOPULSE Suit on functional mobility, with particular focus on walking ability and balance. The study will also assess the safety of the device by monitoring any adverse events that occur during the study. Researchers will additionally evaluate the effects of the EXOPULSE Suit on: * Pain * Hand and finger dexterity * Fatigue * Quality of life Participants will be randomly assigned to receive one of the stimulation programs being evaluated in the study. Some participants may receive a sham (placebo) stimulation. Neither the participants nor the study staff performing the assessments will know which stimulation program a participant has been assigned to during the study. This approach, known as blinding, helps ensure that the study results are as objective and reliable as possible. Participants will use the EXOPULSE Suit for one hour every other day during a 4-week home-use period. Clinical assessments will be performed before and after the treatment period to evaluate changes in mobility and other symptoms. It is important to note that individuals may experience the stimulation differently. Some participants may clearly feel the stimulation, while others may feel it only slightly or not at all. Not feeling the stimulation does not necessarily indicate which study group a participant has been assigned to, and a treatment effect may still be possible even when the stimulation is not perceived. To ensure meaningful study results, participants are encouraged to use the EXOPULSE Suit as instructed throughout the study period, even if they do not notice a sensation of stimulation or an immediate improvement in their symptoms. The study uses an adaptive design, meaning that an interim analysis will be performed during the study to determine the number of participants needed to reliably evaluate the study objectives.
Conditions
- Multiple Sclerosis
Interventions
Electrostimulation suitDevice
One hour stimulation with an electrostimulation suit every other day. The EXOPULSE Suit provides low-intensity sensory electrical stimulation below the motor threshold. Unlike neuromuscular electrical stimulation (NMES), it is not intended to induce muscle contractions. The stimulation is conceptually similar to TENS but is delivered at lower intensities.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Balance responder rate: Percentage of patients achieving a clinically meaningful improvement in balance, as measured by the Berg Balance Scale (BBS), in the treatment group compared with sham-control group.Time frame: From Baseline 1 (start of treatment) to the post-treatment assessment after 28 days of treatment (-3/+10 days).
1 more outcomes with a free account
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Shirley Ryan AbilityLab
Chicago, Illinois
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.